智通财经APP讯，昭衍新药(06127)发布公告，公司股东顾晓磊及其一致行动人顾美芳于2026年3月17日披露了减持计划，自减持计划公告之日起3个交易日后的3个月内，股东顾晓磊通过上海证券交易所以集中竞价的方式减持不超过502.06万股，大宗交易的方式减持不超过1004.12万股，合计减持不超过1506.18万股，不超过公司总股本的2.01%;股东顾美芳通过上海证券交易所以集中竞价的方式减持不超过247.28万股，大宗交易的方式减持不超过494.56万股，合计减持不超过741.84万股，不超过公司总股本的0.99%。顾晓磊及其一致行动人顾美芳合计减持不超过公司总股本的3.00%。
截至2026年6月18日，顾晓磊、顾美芳分别减持1506.18万股、741.84万股，减持计划实施完毕。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.